Developer docs
API playgroundTry for free, no card

Search company profiles

Fluxergy

Full company profile

uuid0000tsl

Namestring
Fluxergy
Legal namestring
Fluxergy Inc.
Websiteurl
fluxergy.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Fluxergy is a privately held medical diagnostics company founded in 2013 and headquartered in Irvine, California, that develops a multimodal point-of-care (POC) testing platform. The platform combines four diagnostic modalities—molecular (PCR), immunochemistry, clinical chemistry, and cytometry—on a single benchtop analyzer (the Fluxergy Analyzer) using modular microfluidic test cards and a proprietary middleware software called Fluxergy Works. This architecture enables sample-to-answer workflows with results delivered in under one hour for molecular assays and approximately five minutes for chemistry panels such as the Basic Metabolic Panel (BMP), replacing the need for multiple dedicated instruments in clinical and veterinary settings.

The company operates a three-pillar revenue model: (1) hardware sales of the Fluxergy Analyzer to healthcare and veterinary customers, (2) recurring revenue from proprietary test card consumables, with current manufacturing capacity of 1.2 million cards annually and stated scalability to 12 million, and (3) an OEM platform licensing model where assay developers retain IP and regulatory ownership while paying Fluxergy for hardware and software access. Go-to-market is executed through direct sales in the United States (with dedicated human diagnostics and equine veterinary specialists), through Fluxergy Europe GmbH in Germany for European distribution, and through OEM development partners globally. Customer segments are organized vertically into Human Health/Clinical Diagnostics, Equine Veterinary Medicine (currently the most evidenced segment with multiple named accounts), and OEM Development Partners.

Fluxergy has raised approximately $50 million across four disclosed funding rounds since 2013, with the most recent $30 million round in May 2020 led by John Tu. The company received CE-IVD marking for its one-hour COVID-19 RT-PCR test in March 2021, enabling European market entry, and has continued to expand through partnerships with NIAID (2024), ACESO (2024), and an asset acquisition from InnaMed Inc. in 2025 to extend its clinical chemistry capabilities.

Short descriptiontext

Fluxergy is a privately held Irvine-based diagnostics company that has developed a single benchpoint-of-care analyzer combining PCR, immunochemistry, clinical chemistry, and cytometry on one platform, serving human healthcare, equine veterinary, and OEM assay development markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, PCR testing platform, multimodal diagnostic platform, veterinary diagnostics, clinical chemistry testing
Industry1 code
PRIMARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
NAICS code4 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Veterinary Services54194
  • Analytical Laboratory Instrument Manufacturing334516
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Point-of-Care Diagnostic Equipment
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Hardware Sales
TypeHardware Sales
Description

Sale of Fluxergy Analyzer instruments to healthcare facilities, veterinary practices, and OEM partners.

fluxergy.com
2Test Card Consumables
TypeUsage Based
Description

Recurring revenue from sale of proprietary test cards (consumables) for use with the Fluxergy Analyzer. Manufacturing capacity of 1.2MM test cards annually, scalable to 12MM.

fluxergy.com
3OEM Platform Licensing
TypeLicensing Royalties
Description

Partners develop and commercialize their own assays on the Fluxergy platform. Partners retain IP and regulatory ownership for their assays while paying for platform access and manufacturing.

fluxergy.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom enterprise pricing based on volume and contract terms
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available. Contact sales for quote.

fluxergy.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Fluxergy Analyzer
Description

The benchtop diagnostic analyzer that runs molecular, immunoassay, clinical chemistry, and cytometry tests

fluxergy.com
+2 more records
Core offering1 text field

Fluxergy develops and manufactures a multimodal point-of-care diagnostic platform consisting of the Fluxergy Analyzer (benchtop instrument), Fluxergy Test Cards (modular consumables), and Fluxergy Works (cloud-connected middleware software). The platform integrates four diagnostic modalities—molecular (PCR), immunochemistry, clinical chemistry, and cytometry—on a single instrument, serving human health and equine veterinary markets with sample-to-answer workflows delivering results in under one hour.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Turnaround time reduced from 1-3 days to 1 hour for equine infectious disease testing
+5 more records
Product overview1 text field

Fluxergy offers an integrated multi-modal point-of-care diagnostic platform consisting of the Fluxergy Analyzer (benchtop instrument), Fluxergy Test Cards (modular consumables), and Fluxergy Works software (middleware/connectivity). The platform supports four distinct testing modalities: Molecular (PCR), Immunochemistry, Clinical Chemistry, and Cytometry—all running on a single analyzer. The product portfolio includes both CE-IVD cleared assays (COVID-19 PCR, HVRe Respiratory Panel) and veterinary assays (Equine Multiplex Reagents, Streptococcus equi, EHV-1, Environmental Salmonella), with a development pipeline including Basic Metabolic Panel, Comprehensive Metabolic Panel, and CBC. Fluxergy operates an open platform model allowing OEM partners to develop and commercialize their own assays on the system.

Product and service9 records
1Fluxergy Analyzer
CategoryHardware / Diagnostic Analyzer
Description

Benchtop diagnostic analyzer that runs molecular assays, immunoassays, clinical chemistry tests, and cytometry tests using fluorescence, colorimetric, electrical potentiometry, and imaging cytometry sensor and fluidics systems. Features a pneumatic fluidic system with six independently controlled channels, area sensor-based optical system using standard CMOS sensors, and custom in-house developed modular electrical motherboard.

2Fluxergy Test Cards
CategoryConsumables / Test Cards
Description

Modular microfluidic chip-based test cards with configurable zones depending on technology required. Supports multiple PCR tests with 12+ markers, immunochemistry panels with 12+ markers, clinical chemistry panels with 12+ markers, multiplex cytometry, and multimodal test cards with up to 30 markers.

3Fluxergy Works
CategorySoftware / Middleware
Description

Proprietary middleware software providing an intuitive user interface to set up, manage, and run Fluxergy Analyzers. Features HIPAA-compliant cloud connectivity with encryption, AI-powered preventative maintenance, fleet management, and seamless EMR/LIMS integration. Assay Modules enable adding new test modalities by loading a file without patches.

4HVRe Influenza / RSV / SARS-CoV-2 Respiratory Panel
CategoryAssay / Diagnostic Test
Description

Multiplex respiratory panel using real-time PCR technology that detects and differentiates between influenza A/B, RSV, and SARS-CoV-2. Delivers results in 75 minutes with room-temperature stable reagents.

5COVID-19 PCR Test Kit
CategoryAssay / Diagnostic Test
Description

Rapid point-of-care PCR test detecting SARS-CoV-2 virus in 65 minutes with 99.64% variant detection coverage. RNA extraction not required; allows sample pooling up to 10 samples. CE-IVD marked.

6Streptococcus equi subsp. equi PCR Reagent
CategoryAssay / Veterinary Diagnostic Test
Description

PCR-based assay detecting the SeM/eqbE gene from equine samples for identification of Strangles disease. Provides results in 1 hour with minimal hands-on time. Designed for equine veterinary practices managing strangles outbreaks.

7Equine Herpesvirus 1 (EHV-1) PCR Reagent
CategoryAssay / Veterinary Diagnostic Test
Description

PCR assay detecting the gB/gD gene for identification of EHV-1 in horses. Important for respiratory and neurological disease detection in equine populations.

8Environmental Salmonella PCR Test Kit
CategoryAssay / Veterinary Diagnostic Test
Description

Environmental biosurveillance test detecting Salmonella in veterinary hospital settings. Delivers results in under 1 hour after 16-24 hour incubation, improving biosecurity and stall turnover.

9Equine Multiplex Reagents
CategoryAssay / Veterinary Diagnostic Test
Description

A 4-in-1 multiplex reagent targeting EHV-1, EHV-4, EIV (Equine Influenza Virus), and S. equi subsp. equi genes. Temperature-stable reagents with simplified dropper bottle workflow.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1National Institute of Allergy and Infectious Diseases (NIAID)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-18
Description

Fluxergy announced collaboration with NIH's NIAID. This represents a significant strategic partnership for the development of diagnostic solutions targeting infectious diseases.

fluxergy.com
2Austere environments Consortium for Enhanced Sepsis Outcomes (ACESO)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-17
Description

Fluxergy announced partnership with ACESO for sepsis detection testing development. ACESO focuses on developing diagnostics for austere and resource-limited environments.

fluxergy.com
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-07-11
Description

Partnership spotlight featuring SMARTmedSolutions collaboration with Fluxergy.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-06-09
Description

Partnership spotlight: Solis BioDyne tested their SOLISFast DNA Polymerase PCR Master Mixes on the Fluxergy point-of-care system. Successfully validated reagent efficacy while Fluxergy imported OEM partner's testing assay to Fluxergy Works platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-20
Description

Fluxergy joined the Wyss Diagnostics Accelerator's Industrial Participant Program as an inaugural member. The Wyss Institute focuses on developing breakthrough diagnostics technologies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-06-30
Description

Mass General Brigham partnered with Fluxergy to evaluate rapid COVID-19 molecular testing system. Major healthcare system collaboration for clinical validation.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cepheid's GeneXpert system is the gold-standard molecular POC platform offering PCR-based diagnostics (including multiplex respiratory and infectious disease panels) at the point of care. Directly competes with Fluxergy's PCR and respiratory menu, with far deeper hospital penetration and FDA-cleared assay menu.

2Abbott
TypeBroad incumbent
Description

Abbott's ID NOW (molecular POC) and i-STAT (chemistry/hematology POC) compete across two of Fluxergy's four modalities. As a diversified diagnostics incumbent with massive commercial reach, Abbott represents the primary large-cap competitor Fluxergy must displace to scale the human-health business.

TypeDirect peer
Description

BioFire's FilmArray multiplex PCR system is a leading syndromic molecular POC platform used in hospital and physician office labs. Competes directly with Fluxergy's multiplex PCR respiratory and infectious disease panels.

TypeBroad incumbent
Description

Roche's cobas Liat and the acquired GenMark ePlex are molecular POC systems with multiplex panels. Roche's global commercial infrastructure and broad assay menu make it a key competitor as Fluxergy tries to expand beyond equine.

TypeBroad incumbent
Description

QuidelOrtho offers Sofia (immunoassay), Triage (cardiac POC), and recently acquired BioFire-adjacent molecular assets. Overlaps with Fluxergy's immunochemistry and molecular POC capabilities across clinical and physician office channels.

TypeBroad incumbent
Description

IDEXX is the dominant veterinary diagnostics company with reference lab services and in-clinic analyzers (Catalyst Dx, ProCyte Dx, SediVue). While primarily reference-lab-centric, IDEXX is the most logical incumbent competitor if Fluxergy tries to expand equine POC into broader companion animal diagnostics.

TypeEmerging player
Description

Visby Medical develops single-use PCR POC devices for infectious disease (sexual health, respiratory). Comparable to Fluxergy as a smaller, growth-stage molecular POC innovator pursuing rapid time-to-result at point of care.

8Talis Biomedical
TypeEmerging player
Description

Talis is developing a molecular POC platform (Talisman) targeting infectious disease applications. Directly comparable as a small-cap, growth-stage POC molecular diagnostics competitor to Fluxergy's PCR offering.

TypeEmerging player
Description

T2 Biosystems offers the T2Dx and T2Bacteria/PanCandida panels for direct-from-sample molecular detection without sample prep. Comparable to Fluxergy as an emerging molecular diagnostics platform targeting rapid clinical and sepsis decision-making.

TypeEmerging player
Description

Mesa Labs (and its acquired Gyros Protein Technologies and related diagnostics assets) is a smaller specialty diagnostics player with overlapping POC and life-sciences reagent exposure. Comparable as a mid-size platform diagnostics peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fluxergy

Point-of-Care Diagnostic Equipmentfluxergy.com

Fluxergy is a privately held Irvine-based diagnostics company that has developed a single benchpoint-of-care analyzer combining PCR, immunochemistry, clinical chemistry, and cytometry on one platform, serving human healthcare, equine veterinary, and OEM assay development markets.

What Fluxergy does

Fluxergy is a privately held medical diagnostics company founded in 2013 and headquartered in Irvine, California, that develops a multimodal point-of-care (POC) testing platform. The platform combines four diagnostic modalities—molecular (PCR), immunochemistry, clinical chemistry, and cytometry—on a single benchtop analyzer (the Fluxergy Analyzer) using modular microfluidic test cards and a proprietary middleware software called Fluxergy Works. This architecture enables sample-to-answer workflows with results delivered in under one hour for molecular assays and approximately five minutes for chemistry panels such as the Basic Metabolic Panel (BMP), replacing the need for multiple dedicated instruments in clinical and veterinary settings.

The company operates a three-pillar revenue model: (1) hardware sales of the Fluxergy Analyzer to healthcare and veterinary customers, (2) recurring revenue from proprietary test card consumables, with current manufacturing capacity of 1.2 million cards annually and stated scalability to 12 million, and (3) an OEM platform licensing model where assay developers retain IP and regulatory ownership while paying Fluxergy for hardware and software access. Go-to-market is executed through direct sales in the United States (with dedicated human diagnostics and equine veterinary specialists), through Fluxergy Europe GmbH in Germany for European distribution, and through OEM development partners globally. Customer segments are organized vertically into Human Health/Clinical Diagnostics, Equine Veterinary Medicine (currently the most evidenced segment with multiple named accounts), and OEM Development Partners.

Fluxergy has raised approximately $50 million across four disclosed funding rounds since 2013, with the most recent $30 million round in May 2020 led by John Tu. The company received CE-IVD marking for its one-hour COVID-19 RT-PCR test in March 2021, enabling European market entry, and has continued to expand through partnerships with NIAID (2024), ACESO (2024), and an asset acquisition from InnaMed Inc. in 2025 to extend its clinical chemistry capabilities.

Fluxergy firmographics

Firmographics
Name
Fluxergy
Legal name
Fluxergy Inc.
Website
https://fluxergy.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
Fluxergy is a privately held Irvine-based diagnostics company that has developed a single benchpoint-of-care analyzer combining PCR, immunochemistry, clinical chemistry, and cytometry on one platform, serving human healthcare, equine veterinary, and OEM assay development markets.
Ownership category
akta.pro rank

Fluxergy industry classification

Industry
Product category
Point-of-Care Diagnostic Equipment
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Veterinary Services (54194), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Point-of-care diagnostics
  • PCR testing platform
  • Multimodal diagnostic platform
  • Veterinary diagnostics
  • Clinical chemistry testing

Where Fluxergy is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Fluxergy business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Hardware Sales: Sale of Fluxergy Analyzer instruments to healthcare facilities, veterinary practices, and OEM partners.
  2. Test Card Consumables: Recurring revenue from sale of proprietary test cards (consumables) for use with the Fluxergy Analyzer. Manufacturing capacity of 1.2MM test cards annually, scalable to 12MM.
  3. OEM Platform Licensing: Partners develop and commercialize their own assays on the Fluxergy platform. Partners retain IP and regulatory ownership for their assays while paying for platform access and manufacturing.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom enterprise pricing based on volume and contract terms

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Fluxergy product offering

Product offering

Core offering

Fluxergy develops and manufactures a multimodal point-of-care diagnostic platform consisting of the Fluxergy Analyzer (benchtop instrument), Fluxergy Test Cards (modular consumables), and Fluxergy Works (cloud-connected middleware software). The platform integrates four diagnostic modalities—molecular (PCR), immunochemistry, clinical chemistry, and cytometry—on a single instrument, serving human health and equine veterinary markets with sample-to-answer workflows delivering results in under one hour.

Product overview

Fluxergy offers an integrated multi-modal point-of-care diagnostic platform consisting of the Fluxergy Analyzer (benchtop instrument), Fluxergy Test Cards (modular consumables), and Fluxergy Works software (middleware/connectivity). The platform supports four distinct testing modalities: Molecular (PCR), Immunochemistry, Clinical Chemistry, and Cytometry—all running on a single analyzer. The product portfolio includes both CE-IVD cleared assays (COVID-19 PCR, HVRe Respiratory Panel) and veterinary assays (Equine Multiplex Reagents, Streptococcus equi, EHV-1, Environmental Salmonella), with a development pipeline including Basic Metabolic Panel, Comprehensive Metabolic Panel, and CBC. Fluxergy operates an open platform model allowing OEM partners to develop and commercialize their own assays on the system.

Differentiator

Problem solved

Functional benefit

Brands

  • Fluxergy Analyzer: The benchtop diagnostic analyzer that runs molecular, immunoassay, clinical chemistry, and cytometry tests
  • Fluxergy Test Cards
  • Fluxergy Works

Products and services

  • Fluxergy Analyzer Benchtop diagnostic analyzer that runs molecular assays, immunoassays, clinical chemistry tests, and cytometry tests using fluorescence, colorimetric, electrical potentiometry, and imaging cytometry sensor and fluidics systems. Features a pneumatic fluidic system with six independently controlled channels, area sensor-based optical system using standard CMOS sensors, and custom in-house developed modular electrical motherboard.
  • Fluxergy Test Cards Modular microfluidic chip-based test cards with configurable zones depending on technology required. Supports multiple PCR tests with 12+ markers, immunochemistry panels with 12+ markers, clinical chemistry panels with 12+ markers, multiplex cytometry, and multimodal test cards with up to 30 markers.
  • Fluxergy Works Proprietary middleware software providing an intuitive user interface to set up, manage, and run Fluxergy Analyzers. Features HIPAA-compliant cloud connectivity with encryption, AI-powered preventative maintenance, fleet management, and seamless EMR/LIMS integration. Assay Modules enable adding new test modalities by loading a file without patches.
  • HVRe Influenza / RSV / SARS-CoV-2 Respiratory Panel Multiplex respiratory panel using real-time PCR technology that detects and differentiates between influenza A/B, RSV, and SARS-CoV-2. Delivers results in 75 minutes with room-temperature stable reagents.
  • COVID-19 PCR Test Kit Rapid point-of-care PCR test detecting SARS-CoV-2 virus in 65 minutes with 99.64% variant detection coverage. RNA extraction not required; allows sample pooling up to 10 samples. CE-IVD marked.
  • Streptococcus equi subsp. equi PCR Reagent PCR-based assay detecting the SeM/eqbE gene from equine samples for identification of Strangles disease. Provides results in 1 hour with minimal hands-on time. Designed for equine veterinary practices managing strangles outbreaks.
  • Equine Herpesvirus 1 (EHV-1) PCR Reagent PCR assay detecting the gB/gD gene for identification of EHV-1 in horses. Important for respiratory and neurological disease detection in equine populations.
  • Environmental Salmonella PCR Test Kit Environmental biosurveillance test detecting Salmonella in veterinary hospital settings. Delivers results in under 1 hour after 16-24 hour incubation, improving biosecurity and stall turnover.
  • Equine Multiplex Reagents A 4-in-1 multiplex reagent targeting EHV-1, EHV-4, EIV (Equine Influenza Virus), and S. equi subsp. equi genes. Temperature-stable reagents with simplified dropper bottle workflow.

Quantifiable outcome

  • Turnaround time reduced from 1-3 days to 1 hour for equine infectious disease testing
  • +5 more outcomes

Companies that use Fluxergy

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Fluxergy technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Fluxergy partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • National Institute of Allergy and Infectious Diseases (NIAID)coreStrategic or Co-development Partner · 18 November 2024Fluxergy announced collaboration with NIH's NIAID. This represents a significant strategic partnership for the development of diagnostic solutions targeting infectious diseases.
  • Austere environments Consortium for Enhanced Sepsis Outcomes (ACESO)coreStrategic or Co-development Partner · 17 January 2024Fluxergy announced partnership with ACESO for sepsis detection testing development. ACESO focuses on developing diagnostics for austere and resource-limited environments.
  • SMARTmedSolutionsminorOEM/ Whitelabel/ Licensing Partner · 11 July 2023Partnership spotlight featuring SMARTmedSolutions collaboration with Fluxergy.
  • Solis BioDynecoreOEM/ Whitelabel/ Licensing Partner · 9 June 2023Partnership spotlight: Solis BioDyne tested their SOLISFast DNA Polymerase PCR Master Mixes on the Fluxergy point-of-care system. Successfully validated reagent efficacy while Fluxergy imported OEM partner's testing assay to Fluxergy Works platform.
  • Wyss Diagnostics AcceleratorcoreStrategic or Co-development Partner · 20 May 2022Fluxergy joined the Wyss Diagnostics Accelerator's Industrial Participant Program as an inaugural member. The Wyss Institute focuses on developing breakthrough diagnostics technologies.
  • Mass General BrighamcoreStrategic or Co-development Partner · 30 June 2020Mass General Brigham partnered with Fluxergy to evaluate rapid COVID-19 molecular testing system. Major healthcare system collaboration for clinical validation.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Fluxergy competitors and assessment

Company assessment

Direct peers

  • Cepheid (Danaher): Cepheid's GeneXpert system is the gold-standard molecular POC platform offering PCR-based diagnostics (including multiplex respiratory and infectious disease panels) at the point of care. Directly competes with Fluxergy's PCR and respiratory menu, with far deeper hospital penetration and FDA-cleared assay menu.
  • bioMérieux (BioFire): BioFire's FilmArray multiplex PCR system is a leading syndromic molecular POC platform used in hospital and physician office labs. Competes directly with Fluxergy's multiplex PCR respiratory and infectious disease panels.

Broad incumbents

  • Abbott: Abbott's ID NOW (molecular POC) and i-STAT (chemistry/hematology POC) compete across two of Fluxergy's four modalities. As a diversified diagnostics incumbent with massive commercial reach, Abbott represents the primary large-cap competitor Fluxergy must displace to scale the human-health business.
  • Roche (GenMark Diagnostics): Roche's cobas Liat and the acquired GenMark ePlex are molecular POC systems with multiplex panels. Roche's global commercial infrastructure and broad assay menu make it a key competitor as Fluxergy tries to expand beyond equine.
  • QuidelOrtho: QuidelOrtho offers Sofia (immunoassay), Triage (cardiac POC), and recently acquired BioFire-adjacent molecular assets. Overlaps with Fluxergy's immunochemistry and molecular POC capabilities across clinical and physician office channels.
  • IDEXX Laboratories: IDEXX is the dominant veterinary diagnostics company with reference lab services and in-clinic analyzers (Catalyst Dx, ProCyte Dx, SediVue). While primarily reference-lab-centric, IDEXX is the most logical incumbent competitor if Fluxergy tries to expand equine POC into broader companion animal diagnostics.

Emerging players

  • Visby Medical: Visby Medical develops single-use PCR POC devices for infectious disease (sexual health, respiratory). Comparable to Fluxergy as a smaller, growth-stage molecular POC innovator pursuing rapid time-to-result at point of care.
  • Talis Biomedical: Talis is developing a molecular POC platform (Talisman) targeting infectious disease applications. Directly comparable as a small-cap, growth-stage POC molecular diagnostics competitor to Fluxergy's PCR offering.
  • T2 Biosystems: T2 Biosystems offers the T2Dx and T2Bacteria/PanCandida panels for direct-from-sample molecular detection without sample prep. Comparable to Fluxergy as an emerging molecular diagnostics platform targeting rapid clinical and sepsis decision-making.
  • Mesa Labs: Mesa Labs (and its acquired Gyros Protein Technologies and related diagnostics assets) is a smaller specialty diagnostics player with overlapping POC and life-sciences reagent exposure. Comparable as a mid-size platform diagnostics peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Fluxergy social profiles

Digital presence

Fluxergy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fluxergy leadership team

Management profile

Number of profiles

Profiles4 records

Fluxergy funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fluxergy M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fluxergy

What does Fluxergy do?

Fluxergy develops and manufactures a multimodal point-of-care diagnostic platform consisting of the Fluxergy Analyzer (benchtop instrument), Fluxergy Test Cards (modular consumables), and Fluxergy Works (cloud-connected middleware software). The platform integrates four diagnostic modalities—molecular (PCR), immunochemistry, clinical chemistry, and cytometry—on a single instrument, serving human health and equine veterinary markets with sample-to-answer workflows delivering results in under one hour.

Is Fluxergy a public or private company?

Fluxergy is a private company. It is classified as venture growth investor backed and is currently operating.

When was Fluxergy founded?

Fluxergy was founded in 2011. It employs 51 to 100 people.

Where is Fluxergy based?

Fluxergy is headquartered in Irvine, United States, in the North America region.

How does Fluxergy make money?

Three revenue lines are on record. Hardware Sales are the primary driver. The others are test Card Consumables and OEM Platform Licensing.

Who are Fluxergy's main competitors?

Direct peers on record are Cepheid (Danaher) and bioMérieux (BioFire). Broad incumbents are Abbott, Roche (GenMark Diagnostics), QuidelOrtho and IDEXX Laboratories. Emerging players are Visby Medical, Talis Biomedical, T2 Biosystems and Mesa Labs.

Does Fluxergy have an API?

No public API is recorded for Fluxergy.

What industry is Fluxergy in?

Fluxergy's product category is Point-of-Care Diagnostic Equipment. Its primary akta.pro industry code is HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldFluxergy corrals CE mark for 1-hour COVID-19 testFluxergy Inc. announced on Thursday that it has received CE-IVD marking for its one-hour COVID-19 real-time polymerase chain reaction (RT-PCR) test. This approval marks the first product cleared for the company's automated diagnostic platform, which is capable of running multiple assay types simultaneously. The certification allows the diagnostic system to be marketed and used within European markets.EquimanagementPCR vs. Culture: Pros and Cons of Testing Technologies for Salmonella spp.A webinar sponsored by Fluxergy featured veterinarians Ben Sykes and Nicola Pusterla discussing the comparative efficacy of PCR and culture testing for detecting Salmonella spp. in equine hospital settings. The experts highlighted that while PCR offers near 100% sensitivity for early detection, culture provides high specificity and antibiogram data, with sample pooling recommended to reduce costs. The discussion emphasized aggressive surveillance and environmental testing to mitigate zoonotic risks and nosocomial outbreaks.Clinical Lab ProductsFluxergy Partners with NIAID to Advance Multimodal POC DiagnosticsFluxergy is partnering with NIAID to enhance molecular testing and sample preparation aimed at improving affordable point-of-care diagnostics for STIs and vaginosis. The initiative will focus on optimizing rapid nucleic acid extraction methods to develop high-sensitivity tests for gram-negative and fungal pathogens. This collaboration is part of Fluxergy's strategy to provide accessible, cost-effective point-of-care solutions in resource-limited healthcare settings.ForbesWhy A Tech Billionaire’s $50 Million Bet On A Covid Testing Firm Is Still Waiting For FDA ApprovalDiagnostic firm Fluxergy remains stuck in regulatory limbo after waiting eight months for FDA approval to market its coronavirus testing analyzer, despite receiving $50 million in funding from Kingston Technology co-founder John Tu. While competitors like Abbott and Quidel have already secured authorization and generated significant revenue, Fluxergy faces a narrowing window of opportunity as vaccine rollouts begin to reduce demand. The delay is attributed to the separate evaluation required for the device's software and the company's lack of prior FDA experience, prompting plans to seek international approvals if domestic clearance does not occur soon.GenomeWebFluxergy, Mass General Brigham Partner to Evaluate Rapid COVID-19 Molecular Testing SystemFluxergy announced a collaboration with Mass General Brigham to evaluate its research-use-only COVID-19 molecular testing platform. The partnership focuses on assessing the performance of Fluxergy's rapid testing system within the healthcare network.OcbjTu’s New BeatKingston Technology co-founder John Tu has invested approximately $50 million in Fluxergy LLC, an early-stage medical diagnostic startup, to ramp up production of its rapid COVID-19 PCR testing system. Kingston Technology Corp. reported record-breaking sales, positioning it as the largest private company in Orange County with estimated revenues nearing $13 billion.PR NewswireFluxergy объявляет о выделении 30 млн. долларов сша на расширение производственных мощностей системы диагностического тестирования в точке наблюдения в течение часа в ответ на COVID-19 пандемиюFluxergy LLC, a California-based diagnostic testing company headquartered in Irvine, announced a $30 million investment to expand manufacturing capacity for its Fluxergy Analyzer testing system in response to the COVID-19 pandemic. The system, which uses PCR technology and microfluidics to identify the SARS-CoV-2 virus in one hour, is expected to enable up to one million tests per month by the end of 2020. The company has filed for Emergency Use Authorization (EUA) with the FDA to allow certified CLIA high-complexity laboratories to use the high-speed COVID-19 testing system.PR NewswireFluxergy annonce 30 millions de dollars pour augmenter la capacité de fabrication de son système de test de diagnostic au point de service d'une heure en réponse au COVID-19Fluxergy LLC, a diagnostic testing company based in Irvine, California, announced a $30 million investment to expand manufacturing capacity for its Fluxergy Analyzer point-of-care testing system in response to the COVID-19 pandemic. The system uses PCR and microfluidics technology to identify the SARS-CoV-2 virus in one hour, and the company has filed for Emergency Use Authorization with the FDA while conducting validation studies with researchers at UC San Diego. Fluxergy aims to produce up to one million tests per month by the end of 2020 to address COVID-19 testing shortages.PR NewswireFluxergy Submits Request For FDA Emergency Use Authorization (EUA) For One-Hour COVID-19 Test At Point-Of-CareFluxergy LLC, a medical diagnostic test company based in Irvine, California, has submitted an Emergency Use Authorization request to the FDA seeking authorization for its high-speed COVID-19 diagnostic test system for point-of-care use. The Fluxergy Analyzer System, which uses PCR and microfluidics technology, demonstrated the ability to identify SARS-CoV-2 virus in under one hour in bench lab tests and in validation tests completed on March 27, 2020 by researchers at UC San Diego. The company stated that the worldwide shortage and inaccessibility of COVID-19 tests have been major impediments to containing the pandemic, and that this test could save significant time compared to centralized laboratory testing.PR NewswireResearchers At UC San Diego Evaluating Potential "One-Hour" COVID-19 Diagnostic Test Developed By Irvine-Based Innovator FluxergyPhysician-scientists at the University of California, San Diego are evaluating a new diagnostic testing system developed by Fluxergy that can identify the SARS-CoV-2 virus in under one hour. The UCSD team is conducting initial benchtop evaluations to validate the system's performance before potentially using it for bedside testing while pursuing FDA Emergency Use Authorization. If validated, this portable technology aims to reduce reliance on centralized labs and accelerate patient diagnosis during the pandemic.